Superworth

Lucid Diagnostics free cash flow LUCD

Cash from operations less capital spending, by quarter and over the last twelve months, from 2021.

Last 12 months, to Jun 30, 2026
n/m
a quarter missing
Latest quarter, Q2 FY26
−$11.3M
Fiscal year 2022
−$31.1M

Lucid Diagnostics' twelve-month free cash flow can't be added up yet: a quarter of its results is missing from our data.

In its latest quarter, Q2 FY26, it was −$11.3M.

Free cash flow over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearFree cash flowChange
FY2022−$31.1Mn/a
FY2021−$18.5Mn/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedFree cash flowOn a year earlierLast 12 months
Q2 FY26−$11.3Mn/an/a
Q1 FY26−$12.3Mn/an/a
Q2 FY25−$10.6Mn/an/a
Q1 FY25−$12.6Mn/an/a
Q1 FY23−$7.1Mn/a−$32.3M
Q4 FY22−$4.3Mn/a−$31.1M
Q3 FY22−$7.3Mn/a−$37.5M
Q2 FY22−$13.5Mn/a−$32.4M
Q1 FY22−$5.9Mn/a−$21.1M
Q4 FY21−$10.7Mn/a−$18.5M
Q3 FY21−$2.2Mn/an/a
Q2 FY21−$2.3Mn/an/a

Against its peers

Companies in Medical - Instruments & Supplies nearest Lucid Diagnostics' size, closest first, today.

CompanyFree cash flow yield
LUCDLucid Diagnosticsn/m
KEQUKewaunee Scientific11.5%
APTAlpha Pro Tech10.3%
NEPHNephrosn/m
PDEXPro DEX3.4%
UTMDUtah Medical Products4.8%
INFUInfuSystem8.3%
EMBCEmbectan/m
TCMDTactile Systems Technology5.0%
MDXGMimedxn/m
MOVMovado10.2%
Peer median8.3%

What the free cash flow tells you

Cash from operations minus capital spending. The cash the company could hand back or reinvest.

Seasonal and lumpy quarter to quarter. The TTM view is the one to trust.

More on Lucid Diagnostics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.